The Lancet, ISSN 0140-6736, 1998, Volume 351, Issue 9106, pp. 893 - 898
To link to full-text access for this article, visit this link: http://dx.doi.org/10.1016/S0140-6736(97)10006-X Byline: Issam Raad (a) Author Affiliation: (a)...
MEDICINE, GENERAL & INTERNAL | BARRIER PRECAUTIONS | CONTROLLED TRIAL | IMMUNOCOMPROMISED PATIENTS | PROSPECTIVE RANDOMIZED MULTICENTER | CRITICALLY ILL | PREVENTION | STAPHYLOCOCCUS-AUREUS BACTEREMIA | SEPSIS | CENTRAL VENOUS CATHETERS | ENDOLUMINAL BRUSH | Bacteremia - microbiology | Bacterial Adhesion | Bacterial Infections - prevention & control | Biofilms | Candidiasis - etiology | Catheterization - methods | Bacterial Infections - etiology | Humans | Catheters, Indwelling - adverse effects | Catheterization, Central Venous - adverse effects | Staphylococcal Infections - etiology | Prevention | Causes of | Nosocomial infections | Complications | Septicemia | Intravenous catheterization | Blood vessels | Infections | Catheters
MEDICINE, GENERAL & INTERNAL | BARRIER PRECAUTIONS | CONTROLLED TRIAL | IMMUNOCOMPROMISED PATIENTS | PROSPECTIVE RANDOMIZED MULTICENTER | CRITICALLY ILL | PREVENTION | STAPHYLOCOCCUS-AUREUS BACTEREMIA | SEPSIS | CENTRAL VENOUS CATHETERS | ENDOLUMINAL BRUSH | Bacteremia - microbiology | Bacterial Adhesion | Bacterial Infections - prevention & control | Biofilms | Candidiasis - etiology | Catheterization - methods | Bacterial Infections - etiology | Humans | Catheters, Indwelling - adverse effects | Catheterization, Central Venous - adverse effects | Staphylococcal Infections - etiology | Prevention | Causes of | Nosocomial infections | Complications | Septicemia | Intravenous catheterization | Blood vessels | Infections | Catheters
Journal Article
Lancet Infectious Diseases, The, ISSN 1473-3099, 2007, Volume 7, Issue 10, pp. 645 - 657
Summary Indwelling vascular catheters are a leading source of bloodstream infections in critically ill patients and cancer patients. Because clinical...
Infectious Disease | ANTISEPTIC-IMPREGNATED CATHETER | INFECTIOUS DISEASES | BLOOD-STREAM INFECTION | PROSPECTIVE RANDOMIZED-TRIAL | INTENSIVE-CARE-UNIT | SILVER-SULFADIAZINE | STAPHYLOCOCCUS-AUREUS BACTEREMIA | CENTRAL-VENOUS-CATHETER | STERILE BARRIER PRECAUTIONS | CRITICALLY-ILL PATIENTS | RAPID DIAGNOSIS | Catheters, Indwelling - classification | Humans | Bacteremia - drug therapy | Anti-Infective Agents - therapeutic use | Bacteremia - diagnosis | Fungemia - prevention & control | Fungemia - diagnosis | Anti-Infective Agents - administration & dosage | Bacteremia - prevention & control | Fungemia - drug therapy | Catheters, Indwelling - adverse effects | Catheterization, Central Venous - adverse effects | Catheterization, Peripheral - adverse effects | Medical equipment | Health aspects | Physiological apparatus
Infectious Disease | ANTISEPTIC-IMPREGNATED CATHETER | INFECTIOUS DISEASES | BLOOD-STREAM INFECTION | PROSPECTIVE RANDOMIZED-TRIAL | INTENSIVE-CARE-UNIT | SILVER-SULFADIAZINE | STAPHYLOCOCCUS-AUREUS BACTEREMIA | CENTRAL-VENOUS-CATHETER | STERILE BARRIER PRECAUTIONS | CRITICALLY-ILL PATIENTS | RAPID DIAGNOSIS | Catheters, Indwelling - classification | Humans | Bacteremia - drug therapy | Anti-Infective Agents - therapeutic use | Bacteremia - diagnosis | Fungemia - prevention & control | Fungemia - diagnosis | Anti-Infective Agents - administration & dosage | Bacteremia - prevention & control | Fungemia - drug therapy | Catheters, Indwelling - adverse effects | Catheterization, Central Venous - adverse effects | Catheterization, Peripheral - adverse effects | Medical equipment | Health aspects | Physiological apparatus
Journal Article
Cancer, ISSN 0008-543X, 06/2008, Volume 112, Issue 11, pp. 2493 - 2499
BACKGROUND. The objective of the current retrospective study was to compare the epidemiology of candidemia and its risk factors in patients who had hematologic...
Cancer patient | Hematologic malignancies | Candidemia | Solid tumors | Epidemiology | RISK-FACTORS | SECULAR TRENDS | ANTIFUNGAL SUSCEPTIBILITY | HOSPITAL-ACQUIRED CANDIDEMIA | candidemia | solid tumors | ATTRIBUTABLE MORTALITY | FUNGAL-INFECTIONS | hematologic malignancies | epidemiology | TORULOPSIS-GLABRATA | IMMUNOCOMPROMISED PATIENTS | ONCOLOGY | INTENSIVE-CARE-UNIT | cancer patient | BLOOD-STREAM INFECTIONS | Hematologic Neoplasms - microbiology | Humans | Middle Aged | Risk Factors | Candidiasis - epidemiology | Male | Hematologic Neoplasms - epidemiology | Candidiasis - microbiology | Fungemia - microbiology | Fluconazole - therapeutic use | Antifungal Agents - therapeutic use | Neutropenia - etiology | Candida - classification | Candida - pathogenicity | Candidiasis - drug therapy | Fungemia - drug therapy | Hematologic Neoplasms - drug therapy | Female | Retrospective Studies | Fungemia - epidemiology | Amphotericin B - therapeutic use | Drug Resistance, Fungal | Catheterization, Central Venous - adverse effects | Cohort Studies | Complications and side effects | Candidiasis | Causes of | Research | Blood diseases | Risk factors
Cancer patient | Hematologic malignancies | Candidemia | Solid tumors | Epidemiology | RISK-FACTORS | SECULAR TRENDS | ANTIFUNGAL SUSCEPTIBILITY | HOSPITAL-ACQUIRED CANDIDEMIA | candidemia | solid tumors | ATTRIBUTABLE MORTALITY | FUNGAL-INFECTIONS | hematologic malignancies | epidemiology | TORULOPSIS-GLABRATA | IMMUNOCOMPROMISED PATIENTS | ONCOLOGY | INTENSIVE-CARE-UNIT | cancer patient | BLOOD-STREAM INFECTIONS | Hematologic Neoplasms - microbiology | Humans | Middle Aged | Risk Factors | Candidiasis - epidemiology | Male | Hematologic Neoplasms - epidemiology | Candidiasis - microbiology | Fungemia - microbiology | Fluconazole - therapeutic use | Antifungal Agents - therapeutic use | Neutropenia - etiology | Candida - classification | Candida - pathogenicity | Candidiasis - drug therapy | Fungemia - drug therapy | Hematologic Neoplasms - drug therapy | Female | Retrospective Studies | Fungemia - epidemiology | Amphotericin B - therapeutic use | Drug Resistance, Fungal | Catheterization, Central Venous - adverse effects | Cohort Studies | Complications and side effects | Candidiasis | Causes of | Research | Blood diseases | Risk factors
Journal Article
Clinical Infectious Diseases, ISSN 1058-4838, 7/2009, Volume 49, Issue 1, pp. 1 - 45
These updated guidelines replace the previous management guidelines published in 2001. The guidelines are intended for use by health care providers who care...
Recommendations | Antibiotics | Antimicrobials | Endocarditis | IDSA Guidelines | Infections | Dialysis | Catheters | Blood | Bacteremia | Staphylococcus | INFECTIOUS DISEASES | BLOOD-STREAM INFECTION | RISK-FACTORS | MICROBIOLOGY | STAPHYLOCOCCUS-AUREUS BACTEREMIA | IMMUNOLOGY | ANTIBIOTIC LOCK TECHNIQUE | LIPOSOMAL AMPHOTERICIN-B | GRAM-NEGATIVE BACTEREMIA | CENTRAL VENOUS CATHETERS | CRITICALLY-ILL PATIENTS | IN-VITRO ACTIVITY | SERRATIA-MARCESCENS BACTEREMIA | Case Management | United States | Humans | Cross Infection - diagnosis | Catheter-Related Infections - diagnosis | Cross Infection - drug therapy | Catheter-Related Infections - drug therapy | Infection | Complications and side effects | Blood-borne diseases | Practice guidelines (Medicine) | Reports | Diagnosis | Intravenous catheterization
Recommendations | Antibiotics | Antimicrobials | Endocarditis | IDSA Guidelines | Infections | Dialysis | Catheters | Blood | Bacteremia | Staphylococcus | INFECTIOUS DISEASES | BLOOD-STREAM INFECTION | RISK-FACTORS | MICROBIOLOGY | STAPHYLOCOCCUS-AUREUS BACTEREMIA | IMMUNOLOGY | ANTIBIOTIC LOCK TECHNIQUE | LIPOSOMAL AMPHOTERICIN-B | GRAM-NEGATIVE BACTEREMIA | CENTRAL VENOUS CATHETERS | CRITICALLY-ILL PATIENTS | IN-VITRO ACTIVITY | SERRATIA-MARCESCENS BACTEREMIA | Case Management | United States | Humans | Cross Infection - diagnosis | Catheter-Related Infections - diagnosis | Cross Infection - drug therapy | Catheter-Related Infections - drug therapy | Infection | Complications and side effects | Blood-borne diseases | Practice guidelines (Medicine) | Reports | Diagnosis | Intravenous catheterization
Journal Article
Lancet, The, ISSN 0140-6736, 2016, Volume 387, Issue 10020, pp. 760 - 769
Summary Background Isavuconazole is a novel triazole with broad-spectrum antifungal activity. The SECURE trial assessed efficacy and safety of isavuconazole...
Internal Medicine | MYCOSES STUDY-GROUP | MEDICINE, GENERAL & INTERNAL | INFECTIONS | THERAPY | PULMONARY ASPERGILLOSIS | PHARMACODYNAMIC TARGET DETERMINATION | CELL TRANSPLANT PATIENTS | EUROPEAN-ORGANIZATION | CLINICAL-PRACTICE | CANCER | LIPOSOMAL AMPHOTERICIN-B | Triazoles - administration & dosage | Triazoles - adverse effects | Antifungal Agents - adverse effects | Injections, Intravenous | Humans | Middle Aged | Male | Antifungal Agents - therapeutic use | Nitriles - administration & dosage | Pyridines - adverse effects | Voriconazole - administration & dosage | Aspergillosis - mortality | Adult | Female | Aspergillosis - drug therapy | Pyridines - therapeutic use | Triazoles - therapeutic use | Pyridines - administration & dosage | Double-Blind Method | Drug Administration Schedule | Voriconazole - adverse effects | Administration, Oral | Voriconazole - therapeutic use | Treatment Outcome | Mycoses - drug therapy | Aged | Mycoses - mortality | Nitriles - adverse effects | Antifungal Agents - administration & dosage | Nitriles - therapeutic use | Mycoses | Clinical trials | Care and treatment | Molds (Fungi) | Studies | Fungi | Transplants & implants | Hematology | Mortality | Fungal infections | Drug therapy
Internal Medicine | MYCOSES STUDY-GROUP | MEDICINE, GENERAL & INTERNAL | INFECTIONS | THERAPY | PULMONARY ASPERGILLOSIS | PHARMACODYNAMIC TARGET DETERMINATION | CELL TRANSPLANT PATIENTS | EUROPEAN-ORGANIZATION | CLINICAL-PRACTICE | CANCER | LIPOSOMAL AMPHOTERICIN-B | Triazoles - administration & dosage | Triazoles - adverse effects | Antifungal Agents - adverse effects | Injections, Intravenous | Humans | Middle Aged | Male | Antifungal Agents - therapeutic use | Nitriles - administration & dosage | Pyridines - adverse effects | Voriconazole - administration & dosage | Aspergillosis - mortality | Adult | Female | Aspergillosis - drug therapy | Pyridines - therapeutic use | Triazoles - therapeutic use | Pyridines - administration & dosage | Double-Blind Method | Drug Administration Schedule | Voriconazole - adverse effects | Administration, Oral | Voriconazole - therapeutic use | Treatment Outcome | Mycoses - drug therapy | Aged | Mycoses - mortality | Nitriles - adverse effects | Antifungal Agents - administration & dosage | Nitriles - therapeutic use | Mycoses | Clinical trials | Care and treatment | Molds (Fungi) | Studies | Fungi | Transplants & implants | Hematology | Mortality | Fungal infections | Drug therapy
Journal Article
Advances in Experimental Medicine and Biology, ISSN 0065-2598, 2015, Volume 830, pp. 157 - 179
Different types of central venous catheters (CVCs) have been used in clinical practice to improve the quality of life of chronically and critically ill...
INFECTIOUS DISEASES | FIBRONECTIN-BINDING PROTEINS | ESCHERICHIA-COLI BIOFILMS | CANDIDA-ALBICANS | MIXED-SPECIES BIOFILMS | MICROBIOLOGY | STAPHYLOCOCCUS-AUREUS ADHESION | MUCOID PSEUDOMONAS-AERUGINOSA | ANTIBIOTIC-IMPREGNATED CATHETERS | CENTRAL VENOUS CATHETERS | CRITICALLY-ILL PATIENTS | EDTA LOCK SOLUTION | Microbial Consortia - physiology | Catheter-Related Infections - etiology | Humans | Biofilms - growth & development | Catheterization, Central Venous - methods | Microscopy, Electron | Candida - classification | Catheter-Related Infections - blood | Catheter-Related Infections - microbiology | Catheters, Indwelling - adverse effects | Bacteria - classification | Bacteria - ultrastructure | Catheterization, Central Venous - adverse effects | Candida - ultrastructure
INFECTIOUS DISEASES | FIBRONECTIN-BINDING PROTEINS | ESCHERICHIA-COLI BIOFILMS | CANDIDA-ALBICANS | MIXED-SPECIES BIOFILMS | MICROBIOLOGY | STAPHYLOCOCCUS-AUREUS ADHESION | MUCOID PSEUDOMONAS-AERUGINOSA | ANTIBIOTIC-IMPREGNATED CATHETERS | CENTRAL VENOUS CATHETERS | CRITICALLY-ILL PATIENTS | EDTA LOCK SOLUTION | Microbial Consortia - physiology | Catheter-Related Infections - etiology | Humans | Biofilms - growth & development | Catheterization, Central Venous - methods | Microscopy, Electron | Candida - classification | Catheter-Related Infections - blood | Catheter-Related Infections - microbiology | Catheters, Indwelling - adverse effects | Bacteria - classification | Bacteria - ultrastructure | Catheterization, Central Venous - adverse effects | Candida - ultrastructure
Journal Article
Clinical Infectious Diseases, ISSN 1058-4838, 2/2011, Volume 52, Issue 4, pp. 427 - 431
This document updates and expands the initial Infectious Diseases Society of America (IDSA) Fever and Neutropenia Guideline that was published in 1997 and...
Recommendations | Antifungals | IDSA GUIDELINES | Infectious diseases | Antibiotics | Antimicrobials | Infections | Fever | Symptoms | Neutropenia | Cancer | INFECTIOUS DISEASES | MICROBIOLOGY | IMMUNOLOGY
Recommendations | Antifungals | IDSA GUIDELINES | Infectious diseases | Antibiotics | Antimicrobials | Infections | Fever | Symptoms | Neutropenia | Cancer | INFECTIOUS DISEASES | MICROBIOLOGY | IMMUNOLOGY
Journal Article
Critical Care Medicine, ISSN 0090-3493, 02/2009, Volume 37, Issue 2, pp. 789 - 791
Anti-infective central venous catheters | Critically ill patients | Catheter-related bloodstream infection | catheter-related bloodstream infection | TRIAL | critically ill patients | PREVENTION | DECREASE | CHLORHEXIDINE | anti-infective central venous catheters | CENTRAL VENOUS CATHETERS | CRITICAL CARE MEDICINE | Sepsis - etiology | Clinical Trials as Topic | Catheter-Related Infections - complications | Humans | Catheter-Related Infections - prevention & control
Journal Article
Clinical Infectious Diseases, ISSN 1058-4838, 2014, Volume 59, Issue suppl_5, pp. S340 - S343
Central lines, which are essential for treating cancer, are associated with at least 400 000 episodes of bloodstream infection in patients with cancer every...
central line–associated bloodstream infections | central venous catheters | prevention and management | Central line-associated bloodstream infections | catheter-related infections | cancer patients | INFECTIOUS DISEASES | NEGATIVE BACILLI | MINOCYCLINE-EDTA | central line-associated bloodstream infections | MICROBIOLOGY | RANDOMIZED CONTROLLED-TRIAL | IMMUNOLOGY | CHILDREN | REMOVAL | LOCK SOLUTION | BACTEREMIA | HEMODIALYSIS | Bacteremia - microbiology | Anti-Bacterial Agents - therapeutic use | Neoplasms - complications | Bacteremia - prevention & control | Humans | Bacteremia - drug therapy | Bacteremia - etiology | Catheterization, Central Venous - adverse effects
central line–associated bloodstream infections | central venous catheters | prevention and management | Central line-associated bloodstream infections | catheter-related infections | cancer patients | INFECTIOUS DISEASES | NEGATIVE BACILLI | MINOCYCLINE-EDTA | central line-associated bloodstream infections | MICROBIOLOGY | RANDOMIZED CONTROLLED-TRIAL | IMMUNOLOGY | CHILDREN | REMOVAL | LOCK SOLUTION | BACTEREMIA | HEMODIALYSIS | Bacteremia - microbiology | Anti-Bacterial Agents - therapeutic use | Neoplasms - complications | Bacteremia - prevention & control | Humans | Bacteremia - drug therapy | Bacteremia - etiology | Catheterization, Central Venous - adverse effects
Journal Article
Current Opinion in Critical Care, ISSN 1070-5295, 10/2013, Volume 19, Issue 5, pp. 453 - 460
Purpose of reviewIn patients with systemic bacterial infections hospitalized in ICUs, the inflammatory biomarker procalcitonin (PCT) has been shown to aid...
Serial measurement | Antibiotic stewardship | Procalcitonin | Intensive care unit | C-REACTIVE PROTEIN | COMMUNITY-ACQUIRED PNEUMONIA | GENE-RELATED PEPTIDE | INTENSIVE-CARE PATIENTS | serial measurement | procalcitonin | antibiotic stewardship | SEPTIC SHOCK | intensive care unit | INTERNATIONAL GUIDELINES | ANTIBIOTIC-TREATMENT | SERUM PROCALCITONIN | CRITICALLY-ILL PATIENTS | DURATION | CRITICAL CARE MEDICINE | Calcitonin Gene-Related Peptide | Critical Care - methods | Decision Making | Calcitonin - blood | Diagnosis, Differential | Intensive Care Units | Protein Precursors - blood | Bacterial Infections - drug therapy | Humans | Biomarkers - blood | Bacterial Infections - blood | Bacterial Infections - diagnosis | Anti-Bacterial Agents - administration & dosage
Serial measurement | Antibiotic stewardship | Procalcitonin | Intensive care unit | C-REACTIVE PROTEIN | COMMUNITY-ACQUIRED PNEUMONIA | GENE-RELATED PEPTIDE | INTENSIVE-CARE PATIENTS | serial measurement | procalcitonin | antibiotic stewardship | SEPTIC SHOCK | intensive care unit | INTERNATIONAL GUIDELINES | ANTIBIOTIC-TREATMENT | SERUM PROCALCITONIN | CRITICALLY-ILL PATIENTS | DURATION | CRITICAL CARE MEDICINE | Calcitonin Gene-Related Peptide | Critical Care - methods | Decision Making | Calcitonin - blood | Diagnosis, Differential | Intensive Care Units | Protein Precursors - blood | Bacterial Infections - drug therapy | Humans | Biomarkers - blood | Bacterial Infections - blood | Bacterial Infections - diagnosis | Anti-Bacterial Agents - administration & dosage
Journal Article
Antimicrobial Agents and Chemotherapy, ISSN 0066-4804, 05/2007, Volume 51, Issue 5, pp. 1656 - 1660
Classifications Services AAC Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit...
IN-VITRO | MINOCYCLINE | ANTIBIOTICS | INFECTIONS | VANCOMYCIN | VIVO ACTIVITIES | HEMODIALYSIS | MICROBIOLOGY | PHARMACOLOGY & PHARMACY | AUREUS | CENTRAL VENOUS CATHETERS | ANTIMICROBIAL LOCK THERAPY | Linezolid | Minocycline - pharmacology | Humans | Minocycline - analogs & derivatives | Acetamides - pharmacology | Bacteremia - microbiology | Daptomycin - pharmacology | Biofilms | Oxazolidinones - pharmacology | Anti-Bacterial Agents - pharmacology | Methicillin Resistance | Staphylococcus aureus - drug effects | Catheterization, Central Venous - adverse effects | Experimental Therapeutics
IN-VITRO | MINOCYCLINE | ANTIBIOTICS | INFECTIONS | VANCOMYCIN | VIVO ACTIVITIES | HEMODIALYSIS | MICROBIOLOGY | PHARMACOLOGY & PHARMACY | AUREUS | CENTRAL VENOUS CATHETERS | ANTIMICROBIAL LOCK THERAPY | Linezolid | Minocycline - pharmacology | Humans | Minocycline - analogs & derivatives | Acetamides - pharmacology | Bacteremia - microbiology | Daptomycin - pharmacology | Biofilms | Oxazolidinones - pharmacology | Anti-Bacterial Agents - pharmacology | Methicillin Resistance | Staphylococcus aureus - drug effects | Catheterization, Central Venous - adverse effects | Experimental Therapeutics
Journal Article